1. Home
  2. CGEM vs HAFC Comparison

CGEM vs HAFC Comparison

Compare CGEM & HAFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$18.40

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo Hanmi Financial Corporation

HAFC

Hanmi Financial Corporation

HOLD

Current Price

$32.67

Market Cap

929.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
HAFC
Founded
2016
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
929.0M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
CGEM
HAFC
Price
$18.40
$32.67
Analyst Decision
Strong Buy
Hold
Analyst Count
8
3
Target Price
$30.13
$32.17
AVG Volume (30 Days)
1.4M
200.0K
Earning Date
05-11-2026
04-21-2026
Dividend Yield
N/A
3.75%
EPS Growth
N/A
22.44
EPS
N/A
0.75
Revenue
N/A
$270,165,000.00
Revenue This Year
N/A
$18.65
Revenue Next Year
$5.20
$7.28
P/E Ratio
N/A
$43.29
Revenue Growth
N/A
15.28
52 Week Low
$5.68
$22.00
52 Week High
$18.76
$32.52

Technical Indicators

Market Signals
Indicator
CGEM
HAFC
Relative Strength Index (RSI) 67.12 63.20
Support Level $11.87 $29.04
Resistance Level N/A N/A
Average True Range (ATR) 1.39 0.63
MACD 0.52 0.09
Stochastic Oscillator 82.34 78.99

Price Performance

Historical Comparison
CGEM
HAFC

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

Share on Social Networks: